Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

Interim result of phase II, prospective, single-arm trial of long-course chemoradiotherapy combined with concurrent tislelizumab in locally advanced rectal cancer

BackgroundNeoadjuvant chemoradiotherapy is the standard treatment for locally advanced rectal cancer, with modest benefits on tumor regression and survival. Since chemoradiotherapy combined with immune checkpoint inhibitors has been reported to have synergic effects. This study aims to explore the s...

Full description

Bibliographic Details
Main Authors: Jiale Gao, Xiao Zhang, Zhengyang Yang, Jie Zhang, Zhigang Bai, Wei Deng, Guangyong Chen, Rui Xu, Qi Wei, Yishan Liu, Jiagang Han, Ang Li, Gang Liu, Yi Sun, Dalu Kong, Hongwei Yao, Zhongtao Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Oncology
Subjects:
rectal cancer
chemoradiotherapy
immune checkpoint inhibitors
neoadjuvant therapy
combination therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1057947/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1057947/full

Similar Items